Effects of conjugated linoleic acid plus n-3 polyunsaturated fatty acids on insulin secretion and estimated insulin sensitivity in men

This source preferred by Fotini Tsofliou

This data was imported from PubMed:

Authors: Ahrén, B., Mari, A., Fyfe, C.L., Tsofliou, F., Sneddon, A.A., Wahle, K.W., Winzell, M.S., Pacini, G. and Williams, L.M.

Journal: Eur J Clin Nutr

Volume: 63

Issue: 6

Pages: 778-786

eISSN: 1476-5640

DOI: 10.1038/ejcn.2008.45

BACKGROUND/OBJECTIVES: Dietary addition of either conjugated linoleic acid (CLA) or n-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFAs) has been shown to alter adiposity and circulating lipids, risk markers of cardiovascular diseases. However, CLA may decrease insulin sensitivity, an effect that may be reversed by n-3 LC-PUFA. Thus, the potential of CLA plus n-3 LC-PUFA to affect insulin secretion and sensitivity in non-diabetic young and old, lean and obese subjects was tested. SUBJECTS/METHODS: CLA (3 g daily) plus n-3 LC-PUFA (3 g daily) or control oil (6 g daily) was given to lean (n=12; BMI 20-26 kg/m(2)) or obese (n=10; BMI 29-35 kg/m(2)) young (20-37 years old) or lean (n=16) or obese (n=11) older men (50-65 years) for 12 weeks. The study had a double-blind, placebo-controlled randomized crossover design, and primary end points were insulin secretion and sensitivity during a standardized meal test, evaluated by modeling glucose, insulin and C-peptide data. RESULTS: The combination was well tolerated. There was no significant difference in fasting levels of glucose, insulin or C-peptide after CLA/n-3 LC-PUFA treatment compared with control oil. Neither insulin secretion nor estimated sensitivity was affected by CLA/n-3 LC-PUFA in lean or obese young subjects or in older lean subjects. However, in older obese subjects, estimated insulin sensitivity was reduced with CLA/n-3 LC-PUFA compared with control (P=0.024). CONCLUSIONS: The results do not support beneficial effects of CLA/n-3 LC-PUFA for beta-cell dysfunction or insulin resistance in humans but suggest that insulin sensitivity in older obese subjects is reduced.

This data was imported from Scopus:

Authors: Ahrén, B., Mari, A., Fyfe, C.L., Tsofliou, F., Sneddon, A.A., Wahle, K.W., Winzell, M.S., Pacini, G. and Williams, L.M.

Journal: European Journal of Clinical Nutrition

Volume: 63

Issue: 6

Pages: 778-786

eISSN: 1476-5640

ISSN: 0954-3007

DOI: 10.1038/ejcn.2008.45

Background/Objectives: Dietary addition of either conjugated linoleic acid (CLA) or n-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFAs) has been shown to alter adiposity and circulating lipids, risk markers of cardiovascular diseases. However, CLA may decrease insulin sensitivity, an effect that may be reversed by n-3 LC-PUFA. Thus, the potential of CLA plus n-3 LC-PUFA to affect insulin secretion and sensitivity in non-diabetic young and old, lean and obese subjects was tested. Subjects/Methods: CLA (3 g daily) plus n-3 LC-PUFA (3 g daily) or control oil (6g daily) was given to lean (n = 12; BMI 20-26 kg/m2) or obese (n = 10; BMI 29-35 kg/m2) young (20-37 years old) or lean (n = 16) or obese (n = 11) older men (50-65 years) for 12 weeks. The study had a double-blind, placebo-controlled randomized crossover design, and primary end points were insulin secretion and sensitivity during a standardized meal test, evaluated by modeling glucose, insulin and C-peptide data. Results: The combination was well tolerated. There was no significant difference in fasting levels of glucose, insulin or C-peptide after CLA/n-3 LC-PUFA treatment compared with control oil. Neither insulin secretion nor estimated sensitivity was affected by CLA/n-3 LC-PUFA in lean or obese young subjects or in older lean subjects. However, in older obese subjects, estimated insulin sensitivity was reduced with CLA/n-3 LC-PUFA compared with control (P = 0.024). Conclusions: The resultsdo not support beneficial effects of CLA/n-3 LC-PUFA for β-cell dysfunction or insulin resistance in humans but suggest that insulin sensitivity in older obese subjects is reduced.

This data was imported from Web of Science (Lite):

Authors: Ahren, B., Mari, A., Fyfe, C.L., Tsofliou, F., Sneddon, A.A., Wahle, K.W., Winzell, M.S., Pacini, G. and Williams, L.M.

Journal: EUROPEAN JOURNAL OF CLINICAL NUTRITION

Volume: 63

Issue: 6

Pages: 778-786

ISSN: 0954-3007

DOI: 10.1038/ejcn.2008.45

This data was imported from Europe PubMed Central:

Authors: Ahrén, B., Mari, A., Fyfe, C.L., Tsofliou, F., Sneddon, A.A., Wahle, K.W., Winzell, M.S., Pacini, G. and Williams, L.M.

Journal: European journal of clinical nutrition

Volume: 63

Issue: 6

Pages: 778-786

eISSN: 1476-5640

ISSN: 0954-3007

BACKGROUND/OBJECTIVES: Dietary addition of either conjugated linoleic acid (CLA) or n-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFAs) has been shown to alter adiposity and circulating lipids, risk markers of cardiovascular diseases. However, CLA may decrease insulin sensitivity, an effect that may be reversed by n-3 LC-PUFA. Thus, the potential of CLA plus n-3 LC-PUFA to affect insulin secretion and sensitivity in non-diabetic young and old, lean and obese subjects was tested. SUBJECTS/METHODS: CLA (3 g daily) plus n-3 LC-PUFA (3 g daily) or control oil (6 g daily) was given to lean (n=12; BMI 20-26 kg/m(2)) or obese (n=10; BMI 29-35 kg/m(2)) young (20-37 years old) or lean (n=16) or obese (n=11) older men (50-65 years) for 12 weeks. The study had a double-blind, placebo-controlled randomized crossover design, and primary end points were insulin secretion and sensitivity during a standardized meal test, evaluated by modeling glucose, insulin and C-peptide data. RESULTS: The combination was well tolerated. There was no significant difference in fasting levels of glucose, insulin or C-peptide after CLA/n-3 LC-PUFA treatment compared with control oil. Neither insulin secretion nor estimated sensitivity was affected by CLA/n-3 LC-PUFA in lean or obese young subjects or in older lean subjects. However, in older obese subjects, estimated insulin sensitivity was reduced with CLA/n-3 LC-PUFA compared with control (P=0.024). CONCLUSIONS: The results do not support beneficial effects of CLA/n-3 LC-PUFA for beta-cell dysfunction or insulin resistance in humans but suggest that insulin sensitivity in older obese subjects is reduced.

The data on this page was last updated at 05:10 on February 17, 2020.